3-氨基-3-苯基-丙醛 | 102877-48-5

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 3-氨基-3-苯基-丙醛
• 英文名称: 3-amino-3-phenyl-propionaldehyde
• 英文别名: 3-Amino-3-phenylpropanal
• CAS: 102877-48-5
• 化学式: C₉H₁₁NO
• mdl: MFCD19206707
• 分子量: 149.192
• InChiKey: XCEAXSRYEFGESE-UHFFFAOYSA-N

物化性质

• 沸点：
  89 °C(Press: 0.01 Torr)
• 密度：
  1.061±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  43.1
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  3-氨基-3-苯基-1-丙醇 在 manganese(IV) oxide 作用下， 生成 3-氨基-3-苯基-丙醛
  参考文献：
  名称：

  Birkofer; Erlenbach, Chemische Berichte, 1958, vol. 91, p. 2383,2385

  摘要：

  DOI：

文献信息

• Heterocylic antiviral compounds
  申请人：Lemoine Remy

  公开号：US20070191335A1

  公开（公告）日：2007-08-16

  Chemokine receptor antagonists, in particular, 3,7-diazabicyclo[3.3.0]octane compounds according to formula (I) wherein R 1 -R 3 R 6c and X 1 are as defined herein are antagonists of chemokine CCR5 receptors which are useful for treating or preventing an human immunodeficiency virus (HIV-1) infection, or treating AIDS or ARC. The invention further provides methods for treating diseases that are alleviated with CCR5 antagonists. The invention includes pharmaceutical compositions and methods of using the compounds for the treating diseases mediated by the CCR5 receptor.

  足迹化学受体拮抗剂，特别是根据式(I)的3,7-二氮杂双环[3.3.0]辛烷化合物，其中R1-R3R6c和X1如本文所定义，是足迹化学CCR5受体的拮抗剂，可用于治疗或预防人类免疫缺陷病毒（HIV-1）感染，或治疗艾滋病或ARC。该发明还提供了用于治疗通过CCR5拮抗剂缓解的疾病的方法。该发明包括药物组合物和使用这些化合物治疗通过CCR5受体介导的疾病的方法。
• PROCESS FOR PRODUCING OPTICALLY ACTIVE BETA-AMINO ALDEHYDE COMPOUND
  申请人：Hayashi Yujiro

  公开号：US20130211139A1

  公开（公告）日：2013-08-15

  The invention relates to a method of producing optically active β-aminoaldehyde compound (3) by reacting imine compound (1-1) or sulfone compound (1-2) with aldehyde compound (2) in the presence of an optically active pyrrolidine compound. wherein each symbol is as defined in the specification.

  该发明涉及一种在存在光学活性吡咯烷化合物的情况下，通过将亚胺化合物（1-1）或砜化合物（1-2）与醛化合物（2）反应来制备光学活性β-氨基醛化合物（3）的方法，其中每个符号如规范中定义。
• Transacylases of the paclitaxel biosynthetic pathway
  申请人：Washington State University Research Foundation

  公开号：US20030108891A1

  公开（公告）日：2003-06-12

  Transacylase enzymes and the use of such enzymes to produce paclitaxel and related taxoids, as well as intermediates in the paclitaxel biosynthetic pathway, are disclosed. Also disclosed are nucleic acid sequences encoding such transacylase enzymes such as (but without limitation) C-13 phenylpropanoid side chain-CoA acyltransferase and benzoyl-CoA:3′-N-debenzoyl-2′-deoxytaxol N-benzoyltransferase.

  揭示了转酰化酶酶及其用于生产紫杉醇及相关紫杉类化合物的用途，以及紫杉醇生物合成途径中的中间产物。还揭示了编码这些转酰化酶酶的核酸序列，如C-13苯丙烷基侧链-CoA酰基转移酶和苯甲酰-CoA:3'-N-去苯甲酰-2'-去氧紫杉醇N-苯甲酰转移酶（但不限于这些）。
• New pharmaceutical combinations for NOS inhibitors
  申请人：Pfizer Inc

  公开号：US20040229911A1

  公开（公告）日：2004-11-18

  The present invention relates to new pharmaceutical uses for compounds that exhibit activity as nitric oxide synthase (NOS) inhibitors. Specifically, it relates to the use of NOS inhibitors, particularly selective neuronal NOS (nNOS) inhibitors, alone or in combination with another active agent, in particular, either an SSRI or an NK-1 receptor antagonist, for the treatment of disorders or conditions the treatment which can be effected or facilitated by altering circadian rhythms. Examples of such disorders and conditions are blindness, obesity, seasonal affective disorder, bipolar disorder; jet lag, circadian sleep rhythms disorder, sleep deprivation, parasomnias, REM sleep disorders, hypersomnia, sleep-wake cycle disorders, narcolepsy and sleep disorders associated with shift work or irregular work schedules; nocturnal enuresis, and restless-legs syndrome.

  本发明涉及表现为一氧化氮合酶（NOS）抑制剂活性的化合物的新药物用途。具体地，涉及使用NOS抑制剂，特别是选择性神经元NOS（nNOS）抑制剂，单独或与另一种活性剂联合使用，特别是SSRI或NK-1受体拮抗剂，用于治疗可以通过改变昼夜节律来达到或促进治疗的疾病或病况。这些疾病和病况的例子包括失明、肥胖症、季节性情感障碍、双相情感障碍、时差反应、昼夜节律睡眠障碍、睡眠剥夺、睡眠障碍、REM睡眠障碍、嗜睡症、睡眠-觉醒周期障碍、嗜睡症和与轮班工作或不规则工作时间表相关的睡眠障碍、夜尿症和不宁腿综合症。
• SUBSTITUTED 3-HETEROAROYLAMINO-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS
  申请人：RUF Sven

  公开号：US20120252809A1

  公开（公告）日：2012-10-04

  The present invention relates to compounds of the formula I, wherein A, D, E, L, G, R 10 , R 30 , R 40 , R 50 and R 60 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are useful for the treatment of diseases such as atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.

  本发明涉及式I的化合物，其中A、D、E、L、G、R10、R30、R40、R50和R60具有声明中指示的含义，它们是有价值的药物活性化合物。它们是蛋白酶卡特普西林A的抑制剂，可用于治疗动脉硬化、心力衰竭、肾脏疾病、肝脏疾病或炎症性疾病等疾病。此外，本发明还涉及制备式I化合物的方法、它们的用途以及包含它们的制药组合物。